Royal Bank of Canada Has $16.45 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

Royal Bank of Canada lessened its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,919 shares of the specialty pharmaceutical company’s stock after selling 7,379 shares during the quarter. Royal Bank of Canada owned approximately 0.94% of ANI Pharmaceuticals worth $16,451,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Maryland State Retirement & Pension System boosted its holdings in shares of ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares during the period. The Manufacturers Life Insurance Company grew its position in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in ANI Pharmaceuticals by 5.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after buying an additional 200 shares during the period. Finally, Federation des caisses Desjardins du Quebec increased its stake in ANI Pharmaceuticals by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after buying an additional 221 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $82.63 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a market cap of $1.88 billion, a PE ratio of 20.92 and a beta of 0.44. The firm’s 50 day moving average price is $81.03 and its 200 day moving average price is $79.38. ANI Pharmaceuticals, Inc. has a twelve month low of $67.98 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.70 earnings per share. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective for the company. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $105.00.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at $14,213,022.48. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $81.84, for a total value of $40,920.00. Following the transaction, the vice president owned 77,390 shares in the company, valued at approximately $6,333,597.60. This trade represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 88,029 shares of company stock worth $6,954,472 in the last 90 days. 8.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.